Antwi Kwadwo, Nicolas Guillaume, Wild Damian, Christ Emanuel
Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland / Centre for Neuroendocrine and Endocrine Tumours, University Hospital Basel, Basel, Switzerland.
Swiss Med Wkly. 2019 Mar 10;149:w20017. doi: 10.4414/smw.2019.20017. eCollection 2019 Feb 25.
Molecular imaging has found numerous applications in oncology as many tumours express or activate tumour specific target molecules or pathways. This relatively new imaging technique results in a better localisation of tumours and improved tumour staging, especially in the setting of hybrid imaging that is in combination with morphological imaging such as computed tomography. In well differentiated neuroendocrine tumours, somatostatin receptor imaging, as one of the first examples of receptor targeted imaging in humans, plays an important role in the diagnostic work-up of these patients. In poorly differentiated neuroendocrine tumours or medullary thyroid carcinoma, 18F-fluorodeoxyglucose PET/CT and dihydroxyphenylalanine PET/CT play an important role due to the limitations of the somatostatin receptor imaging in these tumour entities. These limitations prompted the development of innovations such as radiolabelled somatostatin receptor antagonists for imaging all types of NET and glucagon-like peptide-1 receptor agonists for the imaging of insulinomas. The current review summarises the actual state of knowledge in the field.
由于许多肿瘤表达或激活肿瘤特异性靶分子或信号通路，分子成像在肿瘤学中已得到广泛应用。这种相对较新的成像技术能更好地定位肿瘤并改善肿瘤分期，尤其是在与计算机断层扫描等形态学成像相结合的混合成像中。在高分化神经内分泌肿瘤中，生长抑素受体成像作为人类受体靶向成像的首个实例之一，在这些患者的诊断检查中发挥着重要作用。在低分化神经内分泌肿瘤或甲状腺髓样癌中，由于生长抑素受体成像在这些肿瘤实体中的局限性，18F-氟脱氧葡萄糖PET/CT和二羟基苯丙氨酸PET/CT发挥着重要作用。这些局限性促使了诸如用于成像所有类型神经内分泌肿瘤的放射性标记生长抑素受体拮抗剂以及用于胰岛素瘤成像的胰高血糖素样肽-1受体激动剂等创新技术的发展。本综述总结了该领域的当前知识状态。
